Jupiter Life Line Hospitals to incorporate healthcare subsidiary Holitti Private Limited

Mergers & acquisitions
Healthcare services

Blacklitt Research23 October 20262 min read

Jupiter Life Line Hospitals (NSE: JLHL) has approved the incorporation of a wholly owned subsidiary, Holitti Private Limited, to undertake healthcare services and such other activities, it said in a filing on 23 Oct 2026. The subsidiary is yet to be incorporated, with paid-up share capital of ₹1 lakh.

The subsidiary's stated business and capital

The Board approved the incorporation at its meeting on 23 Oct 2026. The company says the subsidiary will undertake "the business of healthcare services and such other activities", and it will be incorporated in India.

The subsidiary will have paid-up share capital of ₹1 lakh (Rs. 1,00,000), divided into 10,000 equity shares of Rs. 10 each. Jupiter Life Line Hospitals will hold 100% of it, and the consideration is cash. The approval required is from the Ministry of Corporate Affairs.

How it fits the company

The step is small against the company's size: the initial capital is ₹1 lakh, while the company's market value is ₹1,600 crore at the 23 Oct 2026 close. The company's latest quarter, Q1 FY27 on a consolidated basis, reported total income of ₹421.57 crore and net profit of ₹37.51 crore.

What the subsidiary means for Jupiter Life Line Hospitals' shareholders

The capital put in is nominal, at ₹1 lakh, and the filing does not give the subsidiary's incorporation date, its start date, funding beyond the initial capital, or how its business differs from the company's existing healthcare business. The next step is the incorporation itself, which is subject to MCA approval.

At a glance

Item	Detail
Subsidiary	Holitti Private Limited
Status	Yet to be incorporated, in India
Initial capital	₹1 lakh (10,000 equity shares of Rs. 10 each)
Holding	100% by Jupiter Life Line Hospitals
Stated business	Healthcare services and such other activities
Consideration	Cash

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.